FRESENIUS MED. CARE: H2 recovery should help aim for the low-end of the net income guidance range | BUY | EUR78 vs. EUR81 (+22%)
FRESENIUS MED. CARE - BUY | EUR78 vs. EUR81 (+22%)H2 recovery should help aim for the low-end of the net income guidance range
Q2 EBIT miss triggered a massive sell-off
Expecting H2 recovery …
… to enable the low-end of FME net income guidance range
Slight downward adjustments, FV EUR78 vs EUR81
RegistrarFresenius Medical Care is a kidney dialysis company, operating in both the field of dialysis services and the field of dialysis products for the treatment of end-stage renal disease (ESRD). Co.'s dialysis business is vertically integrated, providing dialysis treatment at dialysis clinics it owns or operates and supplying these clinics with a range of products. In addition, Co. sells dialysis products to other dialysis service providers. In the U.S.A., Co. also provides inpatient dialysis services and other services under contract to hospitals. Co. provides patient services, including renal pharmaceutical products and in the U.S.A., laboratory services.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.